Studies how pioglitazone affects fat cell response to insulin in obesity
Tests pioglitazone against placebo in adults with upper body obesity.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- Insulin Regulation of Lipolysis and Lipolysis Proteins
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 64 people, planned
- Started
- 12 Nov 2018
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Immediate weight loss
- Pioglitazone
- Deferred weight loss
- Placebo
- Record updated
- 28 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 55, either non-obese or obese, to study how insulin controls fat breakdown and how pioglitazone affects it.
- Age
- 18 to 55 years
- Sex
- Men and women (women must be premenopausal)
- Disease stage
- Non-obese adults with BMI 18-25, or obese adults with BMI 30-38
Main reasons for not taking part
- Established New York Heart Association (NYHA) class III or IV heart failure
- Known allergy to pioglitazone or any other component of ACTOSE
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Men and Women between the ages of 18 and 55
- Women will be premenopausal
- Non obese adults BMI between 18-25
- Obese BMI 30-38
Who cannot take part
- Initiation in patients with established New York Heart Associations (NYHA) class III or IV Heart failure
- Use in patients with known hypersensitivity to pioglitazone or any other component of ACTOSE
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Where in United States
- Mayo Clinic in RochesterRochester, United StatesContact: Pamela A ReichTaking people
About the trial
What the trial wants to find out
These studies will define the abnormalities in the adipocyte proteins that are involved in the failure of insulin to suppress lipolysis normally in humans with upper body obesity and will help discover the mechanism by which pioglitazone, a medication used to treat type 2 diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid metabolism.
The 4 groups in the trial
- Immediate weight loss - placeboExisting treatment, for comparison
Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to placebo during this period.
Treatment: Immediate weight loss and Placebo
- Deferred control group - placeboPlacebo, for comparison
After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are also randomized to placebo. At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without placebo.
Treatment: Deferred weight loss and Placebo
- Immediate weight loss - pioglitazoneExisting treatment, for comparison
Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to pioglitazone during this period.
Treatment: Immediate weight loss and Pioglitazone
- Deferred group - pioglitazoneExisting treatment, for comparison
After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are randomized to pioglitazone. They will be monitored to prevent the usual but modest weight gain associated with pioglitazone. They will be on pioglitazone during the 'wait' period. At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without pioglitazone.
Treatment: Pioglitazone and Deferred weight loss
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Insulin Regulation of Lipolysis and Lipolysis Proteins
- Plain-language title
- Studies how pioglitazone affects fat cell response to insulin in obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT03866408, who can take part
- Record updated
- 28 January 2026